CANCELLED Due to possible updates by NIH – will be presented at a later date.
ORA Noon Conference offered via Zoom
SAVE THE DATE! April 21, 2021 at 1:00 pm
Topic: Writing NIH Other Support Pages
Required Changes as of May 25, 2021
Please register in advance for this meeting:
After registering, you will receive a confirmation email containing information about joining the meeting.
OUHSC GeroScience T32 is looking for Post-Doctoral Fellows & Graduate Students
For additional information refer to the attached document.
NIH REMINDER: Required Use of Two-Factor Authentication Using Login.Gov for eRA's External Modules in 2021 (NOT-OD-21-040)
Office of Technology Commercialization Event: Copyright, Trademark and Open Source
Wednesday, April 28, 2021 and 12 p.m. (CDT)
See attached document for additional information.
Pew-Stewart Scholar Program for Cancer Research
The Pew-Stewart Scholars Program for Cancer Research supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer. The program is in line with the Stewart Trust's mission to invest in innovative, cutting-edge, basic cancer research that may accelerate and advance progress toward a cure for cancer; one application can be submitted from the Stephenson Cancer Center. Pre-proposals are being requested from interested early-stage faculty performing cancer research.
Award Amount: $300,000 in flexible support—$75,000 per year
Award Period: Four-years
Pre-Proposal Deadline: May 3, 2021
Please see attachment for information on Eligibility and Pre-Proposal Application Details.
Should you have any questions, please contact CancerResearch@ouhsc.edu.
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry
(click here for more information, or email firstname.lastname@example.org or email@example.com).
- Johnson & Johnson is seeking to engage with academic partners to:
- Improve the precision of immunotherapies through cell targeting – focusing on rheumatology, dermatology, GI inflammation and other inflammatory diseases.
- Detect gut barrier dysfunction – focusing on chronic inflammatory diseases.
- Promote resolution of inflammation by driving pro-resolution responses in innate immune cells focusing on autoimmune and/or chronic inflammatory diseases.
Submission entails a 1-pg non-confidential summary of technology (deadline 4/23/2021)
- A company (requested anonymity) is seeking to engage with academic partners to:
- Develop lymphatic-based disease solutions – focusing on minimally invasive treatments
Submission entails a 1-pg non-confidential summary of technology (deadline 5/7/2021)
- Pfizer’s Centers for Therapeutic Innovation (https://www.pfizercti.com) is seeking collaborative proposals for developing novel therapeutic targets with application in:
- Oncology: tumor targeted, immuno-oncology, cancer vaccines
- Internal medicine: obesity/cachexia, heart failure, diabetic/CKD, NASH/T2D
- Inflammation and immunology: rheumatology, gastroenterology, medical derm
- Rare disease: cardiology, neuro-musc., metabolic, hematology
Preference is for novel biological targets supported by in vivo and in vitro models, enabling genetics and mechanistic insights, translational biochemical or cellular assay and biomarkers. Out of scope: drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies.
Proposal template available upon request (submission deadline 6/18/21).
UPDATE: HSC COVID-19 Response Plan - effective April 13, 2021
This revised Plan (https://www.ouhsc.edu/coronavirus) includes some minor clarifications to current HSC COVID-19 protocols, as well as some more substantive revisions, including:
Section I Telecommuting – Telecommuting in response to COVID-19 is being phased out.
- By June 2, 2021, at least 50% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By July 1, 2021, at least 75% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By August 1, 2021, 100% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus
Section III Social Distancing and Gatherings – Effective June 1, social distance measurement will be 3 feet, except in patient care and eating areas which remain at 6 feet.
-This information is included in the Response Plan now for planning purposes. Our medical and public health experts are hopeful that more students and employees will be able to complete their vaccine series in the next few weeks.
-The 6-foot requirement remains in effect until June 1. Operations will replace signs at that time.
Section V Cleaning Facilities and Equipment – Updated to reflect changes to cleaning protocols in response to recent CDC guidance on cleaning as well as to scientific data regarding COVID-19 surface transmissions.
There are also changes to reflect current clinic screening processes (Section VIII) and international travel (Sections VII and IX), as well as a number of non-substantive changes made for clarification.
Please ensure your area’s Return to Service Plans are updated to reflect these changes.
PRESBYTERIAN HEALTH FOUNDATION GRANTS – REQUEST FOR APPLICATIONS
The Presbyterian Health Foundation (PHF) will fund $4.15M in grants for 2021. Information on the PHF Grant Programs for Spring 2021 and Guidelines and Application for each of the grant programs listed below may be found at https://research.ouhsc.edu/Resources/PHF-Funding-2021. All guidelines have been recently updated to reflect that funds may not be requested for student tuition and fees. If you have any questions, please email ORA4PHF@ouhsc.edu.
April 30, 2021
REMINDER ON COVID-19 MITIGATION STRATEGIES IN THE RESEARCH ENVIRONMENT
With the current increase in COVID-19 cases across Oklahoma, this is a good time to do the following:
- Encourage everyone on your team to telecommute as much as possible; reducing the number of individuals in buildings and the research environment will help in reducing potential transmission of the virus.
- Follow your approved COVID-19 Standard Operating Procedures for your laboratory; be certain these are current and are posted on the lab door and inside the laboratory.
- Familiarize yourself with OU Health Sciences Center COVID-19 Resources https://www.ouhsc.edu/coronavirus).
- Follow all masking and social distancing guidelines as described in the OUHSC COVID-19 Return Planhttps://www.ouhsc.edu/coronavirus); wash your hands often.
- It’s a good practice to follow the HSC’s COVID-19 protocols even when you are home or in the community – masking, social distancing, and good hand hygiene help protect you, your colleagues, and your loved ones.
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( firstname.lastname@example.org ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
Change to NINDS Administrative Reduction Policy for Modular R01 Awards (NOT-NS-21-053)
Notice of Information Reissuance of PAR-18-307, "Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)”, as a Notice of Special Interest (NOT-OD-21-087) (NOT-OD-21-085)
Notice of Information Reissuance of PAR-18-324, "Testing Interventions for Health-Enhancing Physical Activity (R01-Clinical Trial Optional)" as a Notice of Special Interest (NOT-OD-21-087) (NOT-OD-21-086)
Notice to Extend the Response Date for NOT-OD-21-066, "Request for Information (RFI): Inviting Comments and Suggestions to Advanceand Strengthen Racial Equity, Diversity, and Inclusion in the Biomedical Research Workforce and Advance Health Disparities and Health Equity Research" (NOT-OD-21-105)
NIH Blueprint for Neuroscience Research: Request for Information (RFI) on Neuroimmune Interactions in the Healthy CNS (NOT-AA-21-012)
Notice of Participation of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in PA-21-110 Pilot and Feasibility Studies in Preparation for Substance Use Preventions Trials (R34 Clinical Trial Optional) (NOT-AA-21-019)
Notice of Addition of Clinical Research Operations and Management System (CROMS) Language in PAR-20-309 Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) (NOT-AG-21-021)
Notice of Intent to Publish the Reissuance of PAR-18-420, NINDS Exploratory Clinical Trials (U01 - Clinical Trial Required) (NOT-NS-21-054)
Notice of Intent to Publish a Funding Opportunity Announcement for NIH Bridge2AI Integration, Dissemination, and Evaluation (BRIDGE) Center (U54 Clinical Trial Not Allowed) (NOT-RM-21-021)
Notice of Intent to Publish a Funding Opportunity Announcement for Research Opportunity Announcement for the Data Generation Projects of the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (OT2) (NOT-RM-21-022)
Notice of Special Interest (NOSI): Availability of Administrative Supplements for the Network of the National Library of Medicine (NNLM) Center for Data Science and Delivery of Data Services (NOT-LM-21-006)
HEAL Initiative: Notice of Special Interest (NOSI): Limited Competition to Support Mentorship of Junior Investigators (NOT-NS-21-026)
Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being (NOT-OD-21-087)
Notice of Special Interest: Support for Existing Data Repositories to Align with FAIR and TRUST Principles and Evaluate Usage, Utility, and Impact (NOT-OD-21-089)
Notice of Special Interest (NOSI): Administrative Supplements to Support Enhancement of Software Tools for Open Science (NOT-OD-21-091)
Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (NOT-OD-21-100)
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed) (PAR-21-152) - Deadline June 12, 2021
NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required) (PAR-21-153) Deadline June 12, 2021
NINDS Program Project Grant (P01 Clinical Trial Optional) (PAR-21-181) - Deadline May 25, 2021 and September 25, 2021
Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed) (PAR-21-188) Deadline May 28, 2021 and September 24, 2021
National Institute of General Medical Sciences (NIGMS) Bridges to the Doctorate (T32) (PAR-21-198)
Deadline September 28, 2021and September 27, 2022
Limited Competition: Clinical and Translational Science Awards (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Not Allowed) (PAR-21-203) - Deadline June 21, 2021
Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer’s Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Optional) (PAR-21-207) - Deadline September 15, 2021 and January 26, 2022
Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed) (PAR-21-213) Deadline June 19, 2021 and November 18, 2021
Specialized Alcohol Research Centers (P50 Clinical Trial Optional) (RFA-AA-21-005) - Deadline November 15, 2021
Comprehensive Alcohol Research Centers (P60 Clinical trial Optional) (RFA-AA-21-006) - Deadline November 15, 2021
Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed) (RFA-AG-21-035) - Deadline June 9, 2021
Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer’s Disease and Related Dementias (AD/ADRD) (R61/R33 Clinical Trial Required) (RFA-AG-22-016) - Deadline September 15, 2021
Understanding HIV Reservoir Dynamics (P01, Clinical Trial Not Allowed) (RFA-AI-21-013)- Deadline June 30, 2021
Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional) (RFA-AI-21-018) Deadline August 4, 2021
Proteome Characterization Centers (PCCs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed) (RFA-CA-21-023) Deadline June 30, 2021
Proteogenomic Data Analysis Centers (PGDACs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed) (RFA-CA-21-024) – Deadline June 30, 2021
Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01 Clinical Trial Not Allowed) (RFA-CA-21-025) - Deadline July 30, 2021
Centers on Telehealth Research for Cancer-Related Care (P50 Clinical Trial Required)
(RFA-CA-21-029) - Deadline July 20, 2021
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) Drug Discovery and Development (R43/R44 - Clinical Trial Not Allowed) (RFA-DA-22-019) - Deadline August 10, 2021
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) Drug Discovery and Development (R41/R42 - Clinical Trial Not Allowed) (RFA-DA-22-021) – Deadline August 10, 2021
Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional) (RFA-DK-21-006) - Deadline October 20, 2021
Limited Competition: Revision to the Longitudinal Monitoring of Pancreas Architecture in the Type 1 Diabetes in Acute Pancreatitis Consortium – Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional) (RFA-DK-21-501) - Deadline August 17, 2021
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products (U01) Clinical Trials Not Allowed (RFA-FD-21-031) - Deadline July 13, 2021
Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3/UH3 Clinical Trial Optional) (RFA-HD-21-033) - Deadline May 20, 2021
BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) (RFA-MH-21-180) Deadline November 23, 2021 and July 12, 2022
BRAIN Initiative: Targeted BRAIN Circuits Projects-Targeted BCP (R01 Clinical Trial Not Allowed) (RFA-NS-21-013) – Deadline July 7, 2021 and November 10, 2021
BRAIN Initiative: Targeted BRAIN Circuits Planning Projects-Targeted BCPP (R34 Clinical Trials Not Allowed) (RFA-NS-21-014) - Deadline July 7, 2021 and November 10, 2021
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional) (RFA-RM-21-015) - Deadline September 10, 2021
Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed) (RFA-RM-21-020) - Deadline July 15, 2021
OTHER FEDERAL DEADLINES
Department of Defense (DOD) – Gulf War Illness Research Program (GWIRP) – Idea Award – Required Preapplication due May 7, 2021
DOD – GWIRP – Research Advancement Award – Required Preapplication due May 7, 2021
DOD – GWIRP – Clinical Evaluation Award – Required Preapplication due May 7, 2021
DOD – GWIRP – Therapeutic/Biomarker Trial Award – Required Preapplication due May 7, 2021
DOD – GWIRP – New Investigator Award – Required Preapplication due May 7, 2021
DOD – Prostate Cancer Research Program (PCRP) – Early Investigator Research Award – Required Preapplication due June 17, 2021
DOD – PCRP – Early Investigator Research Award – Required Preapplication due June 17, 2021
DOD – PCRP – Physician Research Award – Required Preapplication due June 17, 2021
DOD – PCRP – Translational Science Award – Required Preapplication due July 15, 2021
DOD – PCRP – Health Disparity Research Award – Required Preapplication due July 15, 2021
DOD – PCRP – Idea Development Award – Required Preapplication due September 2, 2021
DOD – PCRP – Clinical Consortium Award – Required Preapplication due September 2, 2021
DOD – PCRP – Data Science Award – Required Preapplication due July 15, 2021
DOD – PCRP – Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award – Required Preapplication due July 15, 2021
Alzheimer’s Drug Discovery Foundation (ADDF) – Accelerating Drug Discovery for Frontotemporal Degeneration – Letter of Intent Deadline May 28, 2021
ADDF – Program to Accelerate Clinical Trials (PACT) – Letter of Intent Deadline May 28, 2021